Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
A prospective non-randomized open label clinical trial to research the efficacy and safety of
sirolimus in patients with symptomatic, recurrent uterine fibroids or/and various rare
leiomyoma.